Clinical studies
As a university institution, the Department of Medicine and Polyclinic I participates in clinical trials to test new drugs or new applications for existing drugs and new procedures in order to pave the way for new and safe treatment options.
A distinction is made between non-commercial clinical trials, also known as investigator initiated trials (IIT), and commercial clinical trials where the sponsor is a pharmaceutical company.
Below you will find an overview of current IIT trials for which patients arestill being sought .
Study participation
Dear patient,
Do you suffer from a cardiological disease and would like to support our clinic in the area of clinical research as part of your treatment and benefit from intensive care? Below you will find further information on investigator-initiated clinical trials currently being conducted at our clinic.
If you have any questions or inquiries, please contact us by phone or e-mail:
MED I - Study Center
Aortic valve studies and other studies
Further information on the studies funded by the DZHK can also be found on the volunteer information platform.
CABA-HFPEF-DZHK27
Do you suffer from heart failure in combination with atrial fibrillation? The CABA-HFPEF-DZHK27 study is investigating whether catheter ablation achieves better results than drug treatment. You can find more information here.
CLOSURE-AF-DZHK16
Have you been diagnosed with atrial fibrillation and have an increased risk of stroke and/or bleeding? You can find more information here.
CMR-ICD-DZHK23
Do you suffer from non-ischemic dilated cardiomyopathy (NIDCM)?The study is investigating whether a scarred heart in patients with NIDCM could be an additional criterion with which doctors can recognize whether the implantation of a defibrillator makes sense. Further information can be found here.
EPIDAURUS (our clinic is the study center)
is a randomized, multicenter and international clinical trial testing whether intensified blood thinning therapy (with a potent P2Y12 inhibitor) after successful dilation of narrowed coronary arteries using a catheter (after PCI) can reduce ischemic events over one month without a significant increase in bleeding complications. Our patient population represents patients with atrial fibrillation and ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) after PCI.
EVERY-VALVE (our clinic is the study center)
In the EVERY-VALVE registry, clinical and imaging data (echocardiography, CT, angiography) of 2370 TAVI patients are recorded and evaluated. Various clinically relevant questions, such as the influence of occlusion system types on vascular and bleeding complications, the influence of procedural aspects (such as post-dilatation, prosthesis type, calcification pattern) on late effects, in particular conduction disorders after TAVI, predictors of stroke risk and mortality after TAVI, predictors of mortality after TAVI, have already been answered. In addition to the main analyses for the entire TAVI cohort, gender-specific analyses will also be performed.
eXPLORE
With the eXPLORE study, the LMU Clinic is investigating the potential and effectiveness of digitalized therapies for high blood pressure. In addition to the usual treatment by their GP or cardiologist, patients receive an individual and extended treatment plan that is made available to them via their smartphone. This improvement in treatment can sustainably improve the health of participating patients. Further information can be found here.
FAIR-HF2-DZHK5
Do you suffer from cardiac insufficiency/heart failure with a simultaneous iron deficiency? You can find more information here.
Munich Heart Study
The aim of this study is to investigate the efficiency and effectiveness of a digital therapy for patients with coronary heart disease (CHD) that supplements standard care. Further information can be foundhere.
Contact person at the clinic: Prof. Dr. med. Stefan Kääb/PD Dr. med. Moritz Sinner
PROTAGORAS (here is our clinic study center)
is an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled Phase III trial testing whether heparin antagonization with protamine reduces post-procedural bleeding complications after TAVR without increasing ischemic events (for more information please contact our study team).
Reduce-MFA-DZHK-25
Do you have aortic stenosis and pronounced myocardial fibrosis? This study investigates the influence of antifibrotic therapy on the regression of myocardial fibrosis after catheter-assisted aortic valve implantation (TAVI) in patients with aortic stenosis and high fibrosis load. Further information can be found here.
SPIRIT-HF-DZHK8
Do you suffer from heart failure with moderately reduced or preserved pumping function? You can find more information here.
TORCH-Plus-DZHK21
DZHK TORCH-Plus-DZHK21 marks the start of the second phase of the Germany-wide database on cardiomyopathies. Further information can be found here.
TransitionCHF-DZHK2
Has your doctor detected a reduced cardiac output during a routine examination without you showing the typical symptoms such as reduced performance or shortness of breath? You can find more information here.
TRINITY-DZHK26 (here is our clinic study center)
You suffer fromheart failure with impaired heart function and your treating physician has diagnosed a chronicdiagnosed with chronic virus-negative inflammatory cardiomyopathy? You can find further information here.
TRICI-HF-DZHK24 (our clinic is the study center here)
Has your treating physician diagnosed you with an insufficient tricuspid valve ? You can find further information here.
Selected studies with completed patient recruitment
ACEI-COVID-19 (our clinic is the study center here)
In this study, doctors from Medical Clinic I are investigating whether it has an effect on the course of COVID-19 disease if ACE inhibitors are paused or replaced by antihypertensive drugs with a different mechanism of action in COVID-19 patients. You can find more information here.
APPROACH-ACS-AF (our clinic is the study center here)
In this study, researchers at our clinic compared two therapies in patients with atrial fibrillation who had also suffered a heart attack. The researchers wanted to determine which of the two therapies leads to less bleeding. Further information can be found here.
COVID-SMART formerly MR SPOC (our clinic is the study center here)
Have you currently tested positive for the SARSCoV2 coronavirus and have previous cardiovascular diseases such as atrial fibrillation, high blood pressure, coronary heart disease, heart failure, have had heart surgery or are a heavy smoker? See flyer for details. Further information can be found at https://covid-smart.de and here.
DEDICATE-DZHK6
Has your doctor diagnosed you with a disease of the aortic valve with severe calcification leading to a narrowing of the heart valve (aortic valve stenosis) and advised you to have the diseased aortic valve replaced? You can find more information here.
IMPROVE-OCT
Do you have a medical recommendation for a cardiac catheterization to assess the coronary arteries after heart transplantation? You can find further information here.
ISAR-REACT 5
The study compares the two anticoagulant agents ticagrelor and prasugrel. The aim is to make a significant contribution to determining the best antithrombotic therapy for ACS (Acute Coronary Syndrome) patients in order to improve clinical outcomes. Further information can be found here.
KardioNet Digital
is a digital care program for patients with chronic heart failure (reduced pumping capacity of the heart), which is implemented in cooperation with the Bundesverband Niedergelassener Kardiologen e.V. (BNK). Further information can be found here.
Contact person at the clinic: PD Dr. med. Ulrich Grabmaier
Munich BREW (our clinic is the study center here)
Researchers at our clinic were able to show in visitors to the Munich Oktoberfest that the risk of cardiac arrhythmia increases with higher alcohol levels. The study is the first to prospectively investigate a connection between acute alcohol consumption and cardiac arrhythmias, i.e. during or immediately after alcohol consumption, in a large number of test subjects. Further information can be found here.
PROTECTED TAVR
Are you planning a transfemoral aortic valve replacement for a severe narrowing of the aortic valve according to medical recommendation? If so, you have the opportunity to receive this as part of the Protected TAVR study using an already approved protection device (Sentinel) to potentially reduce the risk of stroke.
REBOOT-Paradox
Has your doctor diagnosed you with a special form of aortic valve stenosis, known as "paradoxical aortic valve stenosis"? You can find more information here.
REVACEPT-PCI
Revacept was developed after years of basic research into the binding behavior of platelets to injured vascular sites. The focus was on the binding of platelets to collagen, which only protrudes into the bloodstream in injured vessel walls. The active ingredient Revacept binds specifically to the collagen of the damaged areas and thus prevents platelets from accumulating there. Further information can be found here.
SMART-MI (our clinic is the study center here)
In the SMART-MI study, researchers at our clinic investigated whether the use of implantable cardiac monitors (ICMs) with home monitoring function enables more effective detection of therapy-relevant cardiac arrhythmias in a defined high-risk group. Further information can be found here.
